Comparative analysis of metabolic characteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using 18F-FDG PET/CT imaging

Table 3 Subgroup analysis of metabolic characteristics between HER2-low and HER2-zero under different HR statuses

	HR-positive (n = 139)			HR-negative (Triple-negative) (n = 43)
	HER2-zero (n = 39)	HER2-low (n = 100)	P value	HER2-zero (n = 23)	HER2-low (n = 20)	P value
SUVmax	4.27 (3.07–5.62)	5.64 (3.71–8.79)	0.045*	7.87 (4.34–14.51)	7.36 (5.98–10.42)	0.85
MTV	6.02 (4.10–13.89)	7.14 (3.66–12.27)	0.89	9.09 (4.10–17.66)	4.22 (2.35–8.30)	0.06
TLG	18.60 (7.88–34.67)	21.41 (10.28–48.66)	0.44	31.18 (14.22–102.95)	23.42 (8.75–66.53)	0.18
TLR	1.66 (1.15–2.37)	2.32 (1.46–3.68)	0.03*	2.88 (1.96–5.45)	3.21 (2.26–4.20)	0.90

*P value < 0.05
Data are median followed by interquartile range (IQR) in parentheses. All using Mann-Whitney U test
Abbreviations: HER2 human epidermal growth factor receptor 2, HR hormone receptor, SUVmax maximum standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis, TLR tumor-to-liver SUV ratio

ISSN: 1470-7330